Cargando…
HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
Autores principales: | Hutcheson, R, Agrawal, M, Singh, S, Vishwakarma, R, Chaupin, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747419/ http://dx.doi.org/10.1016/j.jval.2022.09.1710 |
Ejemplares similares
-
P31 Impact of COVID-19 on HTA/PRMA of Medicinal Products in Europe: A Payer Perspective
por: Mycka, J, et al.
Publicado: (2022) -
HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022) -
Impact of COVID-19 pandemic on HTA
Publicado: (2020) -
Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017) -
The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)